Cerenis Therapeutics

Cerenis Appoints Non-Executive Director, CMOCerenis Therapeutics, the pharma company developing new high-density lipoprortein therapies for cardiovascular and metabolic diseases, Tuesday appointed Richard C. Pasternak to the board of directors and John F. Paolini, M.D., as Chief Medical Officer.
Cerenis Initiates Phase 2 Study of Coronary Syndrome TreatmentCerenis Therapeutics, the pharma startup with offices in Toulouse, France and Portage, Tuesday announced the start of a Phase 2 clinical trial of its lead drug candidate, CER-001, in patients with acute coronary syndrome.